EUVIMEDEUVIMED entdecken
Open Access

Identification of Novel DNA Methylation Prognostic Biomarkers for AML With Normal Cytogenetics

Cândida Cardoso iD, Daniel Pestana iD, Sreemol Gokuladhas iD, Ana D Marreiros, Justin M O'Sullivan iD, Alexandra Binnie iD, Mónica TFernandes iD, Pedro Castelo-Branco iD

JCO Clinical Cancer Informatics · 2024

DOI: 10.1200/cci.23.00265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2024. Verfasst von Cândida Cardoso und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve/Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve…. Hauptthemen laut MEDLINE: DNA Methylation, Leukemia, Myeloid, Acute, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE AML is a hematologic cancer that is clinically heterogeneous, with a wide range of clinical outcomes. DNA methylation changes are a hallmark of AML but are not routinely used as a criterion for risk stratification. The aim of this study was to explore DNA methylation markers that could risk stratify patients with cytogenetically normal AML (CN-AML), currently classified as intermediate-risk. MATERIALS AND METHODS DNA methylation profiles in whole blood samples from 77 patients with CN-AML in The Cancer Genome Atlas (LAML cohort) were analyzed. Individual 5’-cytosine-phosphate-guanine-3’ (CpG) sites were assessed for their ability to predict overall survival. The output was validated using DNA methylation profiles from bone marrow samples of 79 patients with CN-AML in a separate data set from the Gene Expression Omnibus. RESULTS In the training set, using DNA methylation data derived from the 450K array, we identified 2,549 CpG sites that could potentially distinguish patients with CN-AML with an adverse prognosis ( intermediate-poor ) from those with a more favorable prognosis ( intermediate-favorable ) independent of age. Of these, 25 CpGs showed consistent prognostic potential across both the 450K and 27K array platforms. In a separate validation data set, nine of these 25 CpGs exhibited statistically significant differences in 2-year survival. These nine validated CpGs formed the basis for a combined prognostic biomarker panel, which includes an 8-CpG Somatic Panel and the methylation status of cg23947872. This panel displayed strong predictive ability for 2-year survival, 2-year progression-free survival, and complete remission in the validation cohort. CONCLUSION This study highlights DNA methylation profiling as a promising approach to enhance risk stratification in patients with CN-AML, potentially offering a pathway to more personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationLeukemia, Myeloid, AcuteBiomarkers, TumorHumansPrognosisFemaleMaleMiddle AgedAgedAdultCpG IslandsAged, 80 and overYoung Adult

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Faculdade de Medicina e Ciências Biomédicas (FMCB), Universidade do Algarve/Faculty of Medicine and Biomedical Sciences (FMCB), University of Algarve, Faro, Portugal.
  • Algarve Biomedical Center Research Institute (ABC-RI), Faro, Portugal.
  • Liggins Institute, The University of Auckland, Auckland, New Zealand.
  • The Maurice Wilkins Centre, The University of Auckland, Auckland, New Zealand.
  • Australian Parkinson's Mission, Garvan Institute of Medical Research, Sydney, NSW, Australia.
  • MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom.

ORCID-Profile: Cândida Cardoso, Daniel Pestana, Sreemol Gokuladhas, Justin M O'Sullivan, Alexandra Binnie, Mónica TFernandes, Pedro Castelo-Branco

Zitieren

APA

Cardoso, C., Pestana, D., Gokuladhas, S., Marreiros, A. D., O'Sullivan, J. M., Binnie, A., TFernandes, M., & Castelo-Branco, P. (2024). Identification of Novel DNA Methylation Prognostic Biomarkers for AML With Normal Cytogenetics. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.23.00265

Vancouver

Cardoso C, Pestana D, Gokuladhas S, Marreiros AD, O'Sullivan JM, Binnie A, et al. Identification of Novel DNA Methylation Prognostic Biomarkers for AML With Normal Cytogenetics. JCO Clinical Cancer Informatics. 2024. doi:10.1200/cci.23.00265

BibTeX
@article{Cardoso2024,
  author = {Cardoso, Cândida and Pestana, Daniel and Gokuladhas, Sreemol and Marreiros, Ana D and O'Sullivan, Justin M and Binnie, Alexandra and TFernandes, Mónica and Castelo-Branco, Pedro},
  title = {Identification of Novel DNA Methylation Prognostic Biomarkers for AML With Normal Cytogenetics},
  journal = {JCO Clinical Cancer Informatics},
  year = {2024},
  doi = {10.1200/cci.23.00265}
}
Kostenlos starten →